NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT06018116 2024-02-15
CANUCK-01
CHU de Quebec-Universite Laval
Phase 2 Withdrawn
NCT00771017 2023-05-25
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT03147196 2019-01-22
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Mayo Clinic
Phase 2 Withdrawn
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT01658527 2016-06-10
TAK-700 in Castration Resistant Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00685633 2013-08-20
Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00003517 2013-07-10
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00244920 2012-05-28
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn